Mortality Risk for Docetaxel-Treated, High-Grade Prostate Cancer With Low PSA Levels: A Meta-Analysis

IMPORTANCE: Patients with high-grade prostate cancer with low levels of prostate-specific antigen (PSA; <4 ng/mL) are at high risk of mortality, necessitating an improved treatment paradigm. OBJECTIVE: To assess for these patients whether adding docetaxel to standard of care (SOC) treatment is as...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahal, Brandon A., Kwak, Lucia, Xie, Wanling, Eastham, James A., James, Nicholas D., Sandler, Howard M., Feng, Felix Y., Brihoum, Meryem, Fizazi, Karim, Sweeney, Christopher, Ravi, Praful, D’Amico, Anthony V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620614/
https://www.ncbi.nlm.nih.gov/pubmed/37910103
http://dx.doi.org/10.1001/jamanetworkopen.2023.40787

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10620614/
https://www.ncbi.nlm.nih.gov/pubmed/37910103
http://dx.doi.org/10.1001/jamanetworkopen.2023.40787

Ejemplares similares